Matinas BioPharma Holdings Inc (MTNB)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $881,570
Last updated: Nov 17, 2026 at 4:10 PM ET
Matinas BioPharma Holdings Inc (MTNB) Stock Chart
Matinas BioPharma Holdings (MTNB) has a latest price of $0.88 on Nov 17, 2026, 94.9% below its 52-week high of $17.40. Its price fell 95.2% over the past 12 months. The month-end price fell 99.9% over the 10 years through Oct 2026, a compound annual decline of 48.3%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $2,803.60 in Feb 2017 and its lowest $1.51 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart MTNB with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for MTNB.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 75.5%, and over 6 months it fell 89.4%. The month-end price fell 99.1% over the 3 years through Oct 2026, a compound annual decline of 79.1%.
| Period | Change |
|---|---|
| 1 month | -46.7% |
| 3 months | -75.5% |
| 6 months | -89.4% |
| 12 months | -95.2% |
| 12 months, with dividends | -95.2% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -99.1% | -79.1% |
| 5 years | -99.8% | -71.7% |
| 10 years | -99.9% | -48.3% |
Price by Year
Its best calendar year was 2019, when the price rose 281.5%, and its weakest was 2024, when it fell 95.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.51 | -82.8% |
| 2025 | $8.79 | +14.9% |
| 2024 | $7.65 | -95.3% |
| 2023 | $162.07 | -56.8% |
| 2022 | $374.81 | -50.5% |
| 2021 | $757.12 | -25.7% |
| 2020 | $1,019.49 | -40.1% |
| 2019 | $1,701.65 | +281.5% |
| 2018 | $446.03 | -48.7% |
| 2017 | $869.57 | -17.1% |
Trading Range
The price is 57.5% below its 50-day average of $2.08 and 86.3% below its 200-day average of $6.46.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.88 | |
| 52-week high | $17.40 | -94.9% |
| 52-week low | $0.81 | +9.6% |
| 50-day average | $2.08 | -57.5% |
| 200-day average | $6.46 | -86.3% |
Price Risk
Over 3 years, its largest fall from a peak was 99.7%.
| Measure | Value |
|---|---|
| 1-year beta | 0.26 |
| Largest fall, 1 year | -95.0% |
| Largest fall, 3 years | -99.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About MTNB
What is MTNB's 1-year price change?
Matinas BioPharma Holdings's price fell 95.2% over the past 12 months. With dividends included, the 12-month total return was -95.2%.
What is MTNB's 5-year price change?
Matinas BioPharma Holdings's month-end price fell 99.8% over the 5 years through Oct 2026, a compound annual decline of 71.7%. These figures leave out dividends.
What is MTNB's 52-week high and low?
Matinas BioPharma Holdings's 52-week high is $17.40 and its 52-week low is $0.81. Its latest price of $0.88 on Nov 17, 2026 is 94.9% below the high.
What is MTNB's beta?
Matinas BioPharma Holdings's 1-year beta against the S&P 500 is 0.26, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 95.0%.
Is the MTNB chart free?
Yes. Advanced Charting for MTNB is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
MTNB pages: Overview, Charting, Earnings, Financials, Statistics, Competitors